| # | Drug | Count |
|---|---|---|
| 0 | MECHLORETHAMINE HYDROCHLORIDE | 19 |
| 1 | BRENTUXIMAB VEDOTIN | 10 |
| 2 | METHOTREXATE SODIUM | 8 |
| 3 | BEXAROTENE | 7 |
| 4 | METHOTREXATE | 7 |
| 5 | PREDNISONE | 7 |
| 6 | MOGAMULIZUMAB-KPKC | 5 |
| 7 | RUXOLITINIB | 5 |
| 8 | TACROLIMUS | 4 |
| 9 | TACROLIMUS EXTENDED-RELEASE CAPSULES | 4 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | MECHLORETHAMINE HYDROCHLORIDE | 19 | 0.0085 |
| 1 | ALITRETINOIN | 1 | 0.0084 |
| 2 | METHOXSALEN | 1 | 0.0079 |
| 3 | BEXAROTENE | 7 | 0.0053 |
| 4 | MOGAMULIZUMAB-KPKC | 5 | 0.0037 |
| 5 | BEMPEDOIC ACID AND EZETIMIBE | 1 | 0.0014 |
| 6 | PEMIGATINIB | 1 | 0.0012 |
| 7 | BRENTUXIMAB VEDOTIN | 10 | 0.0010 |
| 8 | ROMIDEPSIN | 1 | 0.0006 |
| 9 | SILVER SULFADIAZINE | 1 | 0.0004 |
| # | Drug class | Count |
|---|---|---|
| 0 | Alkylating Drug [EPC] | 21 |
| 1 | CD30-directed Immunoconjugate [EPC] | 10 |
| 2 | Retinoid [EPC] | 10 |
| 3 | Corticosteroid [EPC] | 9 |
| 4 | Folate Analog Metabolic Inhibitor [EPC] | 7 |
| 5 | Chemokine Receptor Type 4 Interaction [EPC] | 5 |
| 6 | Interleukin-23 Antagonist [EPC] | 5 |
| 7 | Kinase Inhibitor [EPC] | 5 |
| 8 | Monoclonal Antibody [EPC] | 5 |
| 9 | Janus Kinase Inhibitor [EPC] | 4 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Photoactivated Radical Generator [EPC] | 1 | 0.0078 |
| 1 | Chemokine Receptor Type 4 Interaction [EPC] | 5 | 0.0037 |
| 2 | CD30-directed Immunoconjugate [EPC] | 10 | 0.0010 |
| 3 | Adenosine Triphosphate-Citrate Lyase Inhibitor [EPC] | 1 | 0.0003 |
| 4 | Histone Deacetylase Inhibitor [EPC] | 1 | 0.0003 |
| 5 | Sulfonamide Antibacterial [EPC] | 1 | 0.0003 |
| 6 | Sulfone [EPC] | 2 | 0.0002 |
| 7 | Interleukin-13 Antagonist [EPC] | 1 | 0.0001 |
| 8 | Human Immunoglobulin G [EPC] | 2 | 0.0001 |
| 9 | Alkylating Drug [EPC] | 21 | 0.0001 |